Outcomes Following Surgical Lung Biopsy for Interstitial Lung Diseases: A Monocenter Experience.


Journal

The Thoracic and cardiovascular surgeon
ISSN: 1439-1902
Titre abrégé: Thorac Cardiovasc Surg
Pays: Germany
ID NLM: 7903387

Informations de publication

Date de publication:
10 2022
Historique:
pubmed: 13 2 2022
medline: 15 10 2022
entrez: 12 2 2022
Statut: ppublish

Résumé

Surgical lung biopsy (SLB) is considered in the investigation of interstitial lung diseases (ILDs) when a complete clinical evaluation and a multidisciplinary discussion (MDD) do not allow the clinician to make a confident diagnosis. Owing to the risk of the procedure, an appropriate assessment of the risk/benefit ratio prior to the intervention is recommended. We aimed to assess the postoperative outcomes and diagnostic yield of SLB for the investigation of ILD in a tertiary care institution. We conducted a retrospective cohort study of consecutive subjects who underwent a SLB for the investigation of ILD in our center from 2009 to 2020. The postoperative mortality and complications rates as well as the diagnostic yield of the procedure were assessed. Of the 1,805 patients newly investigated for ILD in our center from 2009 to 2020, 71 (3.93%) underwent a SLB. At days 30 and 90, the mortality rates were 0 and 2.8%, whereas 4.3 and 7.6% patients experienced an acute ILD exacerbation, respectively. In addition, 4 (5.8%) patients experienced infectious complications and 5 (7.0%) presented prolonged air leaks (all within 30 days). A definite pathological diagnosis was made in 47 (66.2%) patients. Following postoperative MDD, a confident diagnosis was made in 61 patients (85.9%) and resulted in a change of therapy in 49 (69.0%) patients. SLB for the diagnosis of unclassifiable ILDs is associated with low mortality but significant morbidity. However, it results in a confident diagnosis and a change in therapy in the majority of patients.

Sections du résumé

BACKGROUND
Surgical lung biopsy (SLB) is considered in the investigation of interstitial lung diseases (ILDs) when a complete clinical evaluation and a multidisciplinary discussion (MDD) do not allow the clinician to make a confident diagnosis. Owing to the risk of the procedure, an appropriate assessment of the risk/benefit ratio prior to the intervention is recommended. We aimed to assess the postoperative outcomes and diagnostic yield of SLB for the investigation of ILD in a tertiary care institution.
METHODS
We conducted a retrospective cohort study of consecutive subjects who underwent a SLB for the investigation of ILD in our center from 2009 to 2020. The postoperative mortality and complications rates as well as the diagnostic yield of the procedure were assessed.
RESULTS
Of the 1,805 patients newly investigated for ILD in our center from 2009 to 2020, 71 (3.93%) underwent a SLB. At days 30 and 90, the mortality rates were 0 and 2.8%, whereas 4.3 and 7.6% patients experienced an acute ILD exacerbation, respectively. In addition, 4 (5.8%) patients experienced infectious complications and 5 (7.0%) presented prolonged air leaks (all within 30 days). A definite pathological diagnosis was made in 47 (66.2%) patients. Following postoperative MDD, a confident diagnosis was made in 61 patients (85.9%) and resulted in a change of therapy in 49 (69.0%) patients.
CONCLUSION
SLB for the diagnosis of unclassifiable ILDs is associated with low mortality but significant morbidity. However, it results in a confident diagnosis and a change in therapy in the majority of patients.

Identifiants

pubmed: 35151233
doi: 10.1055/s-0041-1740548
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

583-588

Informations de copyright

Thieme. All rights reserved.

Déclaration de conflit d'intérêts

All authors declare that they have no conflict of interest in this study.

Auteurs

Émilie Millaire (É)

Institut Universitaire de Cardiologie et de Pneumologie de Québec Research Center, Université Laval, Quebec City, Quebec, Canada.

Étienne Ouellet (É)

Institut Universitaire de Cardiologie et de Pneumologie de Québec Research Center, Université Laval, Quebec City, Quebec, Canada.

Marc Fortin (M)

Institut Universitaire de Cardiologie et de Pneumologie de Québec Research Center, Université Laval, Quebec City, Quebec, Canada.
Department of Medicine, Université Laval, Quebec City, Quebec, Canada.

Simon Martel (S)

Institut Universitaire de Cardiologie et de Pneumologie de Québec Research Center, Université Laval, Quebec City, Quebec, Canada.
Department of Medicine, Université Laval, Quebec City, Quebec, Canada.

Julie Milot (J)

Institut Universitaire de Cardiologie et de Pneumologie de Québec Research Center, Université Laval, Quebec City, Quebec, Canada.
Department of Medicine, Université Laval, Quebec City, Quebec, Canada.

Lara Bilodeau (L)

Institut Universitaire de Cardiologie et de Pneumologie de Québec Research Center, Université Laval, Quebec City, Quebec, Canada.
Department of Medicine, Université Laval, Quebec City, Quebec, Canada.

Massimo Conti (M)

Institut Universitaire de Cardiologie et de Pneumologie de Québec Research Center, Université Laval, Quebec City, Quebec, Canada.
Department of Medicine, Université Laval, Quebec City, Quebec, Canada.

Steeve Provencher (S)

Institut Universitaire de Cardiologie et de Pneumologie de Québec Research Center, Université Laval, Quebec City, Quebec, Canada.
Department of Medicine, Université Laval, Quebec City, Quebec, Canada.
Pulmonary Hypertension Research Group, Université Laval, Quebec City, Quebec, Canada.

Geneviève Dion (G)

Institut Universitaire de Cardiologie et de Pneumologie de Québec Research Center, Université Laval, Quebec City, Quebec, Canada.
Department of Medicine, Université Laval, Quebec City, Quebec, Canada.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH